Biological Products, (No Diagnostic Substances)·JERUSALEM
Financials
17 shown
Type
Period
Ended
Filed
10-Q
Q3 2025
9/30/25
11/14/25
→
10-Q
Q2 2025
6/30/25
8/8/25
→
10-Q
Q1 2025
3/31/25
5/9/25
→
10-K
FY 2024
12/31/24
3/28/25
→
10-Q
Q3 2024
9/30/24
11/8/24
→
10-Q
Q2 2024
6/30/24
8/9/24
→
↓
Earnings Releases (8-K)
16 shown
Filed
Period
11/14/25
Q4 FY2025
→
8/8/25
Q3 FY2025
→
5/9/25
Q2 FY2025
→
3/28/25
Q1 FY2025
→
11/8/24
Q4 FY2024
→
8/9/24
Q3 FY2024
→
↓
News (8-K)
26 shown
Filed
Type
Description
3/4/26
Reg FD
Regulation FD Disclosure
→
2/9/26
Exec Change
Departure or Appointment of Directors or Certain Officers
→
2/4/26
Exec Change
Entry into a Material Definitive Agreement
→
7/28/25
Reg FD
Regulation FD Disclosure
→
7/18/25
Vote
Submission of Matters to a Vote of Security Holders
→
3/17/25
Agreement
Entry into a Material Definitive Agreement
→
↓
Prospectuses & Registrations
31 shown
Filed
Form
Description
6/6/25
424B3
424B3
→
6/5/25
ARS
ARS
→
5/30/25
S-8
S-8
→
5/30/25
S-3
S-3
→
1/10/25
424B5
424B5
→
8/9/24
S-8
S-8
→
↓
Filing History(369 filings)
TypeDateAccessionPeriodSize
4
Mar 9, 2026
0001178913-26-000787
Mar 5, 2026
5.2 KB
8-K
Mar 4, 2026
0001178913-26-0007148-K
Mar 4, 2026
326.5 KB
4
Feb 17, 2026
0001178913-26-000508
Feb 12, 2026
4.6 KB
4
Feb 11, 2026
0001178913-26-000414
Feb 10, 2026
5.2 KB
4
Feb 11, 2026
0001178913-26-000413
Feb 10, 2026
4.6 KB
4
Feb 11, 2026
0001178913-26-000412
Feb 9, 2026
4.6 KB
4
Feb 11, 2026
0001178913-26-000411
Feb 9, 2026
5.2 KB
3
Feb 9, 2026
0001178913-26-000356
Feb 4, 2026
12.1 KB
8-K
Feb 9, 2026
0001178913-26-0003558-K
Feb 4, 2026
327.5 KB
3
Feb 5, 2026
0001178913-26-000319
Feb 1, 2026
11.8 KB
8-K
Feb 4, 2026
0001178913-26-0003008-K
Jan 29, 2026
939.2 KB
4
Jan 2, 2026
0001178913-26-000020
Jan 1, 2026
7.3 KB
4
Jan 2, 2026
0001178913-26-000018
Jan 1, 2026
7.4 KB
4
Jan 2, 2026
0001178913-26-000017
Jan 1, 2026
7.4 KB
4
Jan 2, 2026
0001178913-26-000016
Jan 1, 2026
10.9 KB
4
Jan 2, 2026
0001178913-26-000015
Jan 1, 2026
7.4 KB
4
Dec 30, 2025
0001178913-25-004125
Dec 29, 2025
5.3 KB
10-Q
Nov 14, 2025
0001178913-25-00385210-Q
Sep 30, 2025
4.3 MB
8-K
Nov 14, 2025
0001178913-25-0038518-K
Nov 14, 2025
313.1 KB
SCHEDULE 13G/A
Nov 14, 2025
0000902664-25-005001
—
11.9 KB
10-Q
Aug 8, 2025
0001178913-25-00270210-Q
Jun 30, 2025
4.3 MB
8-K
Aug 8, 2025
0001178913-25-0027018-K
Aug 8, 2025
306.4 KB
8-K
Jul 28, 2025
0001178913-25-0024848-K
Jul 28, 2025
323.8 KB
4
Jul 18, 2025
0001178913-25-002414
Jul 16, 2025
9.9 KB
4
Jul 18, 2025
0001178913-25-002412
Jul 16, 2025
7.8 KB
25 filings shown
Entera Bio Ltd. — SlamSEC
Proxies
10 shown
Filed
Form
Description
6/5/25
DEFA14A
DEFA 14A
→
6/5/25
DEF 14A
DEF 14A
→
5/14/25
PRE 14A
PRE 14A
→
6/20/24
DEFA14A
DEFA14A
→
6/20/24
DEF 14A
DEF 14A
→
5/29/24
PRE 14A
PRE 14A
→
↓
Ownership
40 shown
Filed
Form
Description
3/9/26
4
4
→
2/17/26
4
4
→
2/11/26
4
4
→
2/11/26
4
4
→
2/11/26
4
4
→
2/11/26
4
4
→
↓
Other Filings
23 shown
Filed
Form
Description
11/14/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
6/6/25
EFFECT
EFFECT
→
4/2/25
SCHEDULE 13G
SCHEDULE 13G
→
1/6/25
SCHEDULE 13G
SCHEDULE 13G
→
2/14/24
EFFECT
EFFECT
→
1/2/24
D
D
→
↓
Entera is a middleware product introduced in the mid-1990s by the Open Environment Corporation (OEC), an early implementation of the three-tiered client–server model development model. Entera viewed business software as a collection of services, rather than as a monolithic application.